
Half year results: Global growth
Sales exceed forecast

Psilocybin clinical trial update

Happy new year

Launch of Products in the UK

Sales are climbing
Results of rights issue ~$1.2m

New product for NZ
We are really proud to launch a new dried flower product to the New Zealand market.

Sales update
E ngā iwi, ngā hapū, me ngā whānau o te motu, tēnā koutou katoa.
As we are in a period of capital raising, it is important we update you with the latest sales information as you consider the pro-rata rights offer.
With only 3 weeks of sales in November, we are experiencing record months in both New Zealand and Australia. With an additional week of sales remaining, this will only further this increase.

Revenue 5x
Hikurangi maunga. The first place in the world to see the sun.
Live webinar
Rights Issue Offer
Rua Bioscience is announcing a Rights Offer to existing shareholders
Sales, Capital Raise and Meetings
Rua Rau Hiwa is sourced under New Zealand's unique regulatory framework, which permits the inclusion of legacy genetics in the medicinal cannabis sector, Rau Hiwa T23 pays homage to the safekeepers of distinctive cannabis genetics in our community and Aotearoa, New Zealand.
Rua Bioscience releases Annual Report (FY24)
Rua releases Full Year Results (FY24)

Legacy cannabis genetics in Australia
Products, Patients and Podcast
Our latest update on Rua Bioscience

Market Insights and Update
Market Insights and Update slides from Rua Bioscience.

Nimbus Health Agreement Extended
Rua Bioscience extends its sales and distribution agreement with Nimbus Health of Germany

Expansion of Compassionate Access Programme
The Compassionate Access Programme has expaned to 37 patients per month thanks to the generosity of others.